Study design: A randomized, double-blind, placebo-controlled clinical trial. Objective: To assess the effect of alpha-lipoic acid (ALA) supplementation on IL-6, hs-CRP, FBS, anthropometric indices, food intake and blood pressure in male patients with chronic spinal cord injury (SCI). Setting: Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. Methods: Fifty-eight men with chronic SCI participated in the study. Participants were divided in two groups: one group received 600 mg of supplemental ALA (n = 28) and the other group received placebo (n = 30) for 12 weeks. At the beginning and end of the study, biochemical parameters, anthropometric indices, blood pressure and dietary intakes were measured. Dietary intake was measured using N4 software, and statistical analyses were carried out using SPSS16. Results: No significant reduction was found in IL-6 (P = 0.97) and hs-CRP levels (P = 0.23). There was significant reduction in fasting blood sugar (P = 0.001), body weight (P = 0.001), BMI (P = 0.001), waist circumference (P = 0.001) and blood pressure (P = 0.001). Dietary intake was significantly reduced, including fat (P = 0.001), carbohydrate (P = 0.001), protein (P = 0.002) and energy intakes (P = 0.001). Conclusion: Lipoic acid supplementation had no significant effect on the measured inflammatory markers but it reduces fasting blood sugar, anthropometric parameters, food intake and blood pressure in men with chronic SCI. Spinal Cord (2015) 53, 621-624; doi:10.1038/sc.2015.35; published online 10 March 2015 INTRODUCTION Alpha-lipoic acid (ALA) or thiocitic acid is an eight-carbon, sulfurcontaining compound. It functions as a cofactor in the multienzyme complexes that catalyze the oxidative decarboxylation of α-keto acids. 1 There is general agreement about the antioxidant properties of ALA, which is thought to work by scavenging free radicals directly, chelating metallic ions, increasing intracellular glutathione and activating endogenous antioxidant systems. 2,3 ALA's antioxidant properties are thought to inhibit the deleterious mechanisms associated with inflammation; however, a number of studies suggest contradictory effects for ALA on inflammatory markers such as IL-6 and C-reactive protein (CRP). [4][5][6] Apart from the antioxidant properties of ALA, it is found to increase nitric oxide synthesis through which endothelial function is probably improved. 7 In addition, ALA reduces body weight and changes other anthropometric indices by suppressing appetite and increasing metabolism. [8][9][10][11][12] Spinal cord injury (SCI) is a devastating condition and entails considerable burden on the individual and society. 13,14 Persons with chronic SCI are at increased risk for obesity, cardiovascular disease, hypertension, diabetes, dyslipidemia and systemic inflammation [15][16][17][18][19] because of changes in their lifestyle, body composition and fat mass. 20 However, these complications may be preventable and treatable. 21 Studying the effect of ALA on cardiovascular risk factors and ...

The aim of this study was to compare two surgery methods including radial shortening and radial shortening combined with vascularized bone graft for treatment of stage II or IIIa of Kienböck's disease. It is a randomized, controlled clinical trial, which was carried out in 2011–2013. Twenty-four patients were assigned equally to radial shortening group (A) or radial shortening combined with vascularized bone graft group (B). The outcome was assessed by Mayo Wrist score before and 9 months after surgery. The mean Mayo Wrist score (SD) was 27.1 (15.4) and 32.5 (18.3) before surgery and 74.6 (5.4) and 85.8 (5.1) after surgery for groups A and B, respectively. The mean score increased in both groups, and it was higher in group B significantly. Radial shortening combined with vascularized bone graft is a valuable method which can be more effective than radial shortening alone, in early stages of Kienböck's disease. This trial is registered with IRCT201404127841N5.

Background:Although several studies have investigated the association between ovarian cancer risk and nonisoflavone flavonoids intake, these findings are inconsistent. This systematic review of published epidemiological studies was conducted to summarize and clarify the evidence on the association between ovarian cancer incidence and nonisoflavone flavonoids intake.Materials and Methods:PubMed, Scopus, Google Scholar, and EMBASE databases were searched based on MeSH term (ovarian neoplasm in combination with flavonoids) to identify related English and non-English papers published up to June 2016. We summarized the results of the relevant studies in this review.Results:In total, seven studies (four with cohort and three with case–control design) included in this review. The results of conducted cohort studies show no relation between ovarian cancer risk and total nonisoflavone flavonoids intake, and only one study reported a significant reduction between ovarian cancer incidence and kaempferol and luteolin intake. Similar to those in the cohort studies, also in case–control studies, no association was found between total nonisoflavone flavonoids intake and ovarian cancer risk, just an inverse association between flavonols intake and ovarian cancer was reported.Conclusion:Several studies investigated the relation of nonisoflavone flavonoids intake and ovarian cancer risk; none of them reported any association for total nonisoflavone flavonoids intake, but some reported an inverse association between certain subclasses or individual flavonoids. These findings are limited, and there is a need for further and more accurate researches to be confirmed.

No abstract

Although several animal and human studies have investigated the effect of alpha-lipoic acid (ALA) on blood pressure (BP), these findings are inconsistent. This systematic review of randomized clinical trials was conducted to summarize the evidence on the effect of ALA on BP. PubMed, SCOPUS, and Google Scholar databases were searched based on MESH term (“Thioctic acid” in combination with “Hypertension” and “Blood pressure”) to identify related papers published up to December 2015. We summarized the results of the relevant studies in this review. In total, nine studies included in this review, seven parallel-designed trials and two crossover-designed trials. The results of parallel-designed studies are inconsistent. Five studies indicate no significant effects for ALA supplementation on BP, but two trials show effects on BP. Unlike parallel-designed trials, two crossover-designed trials have shown similar results and both report no effect for ALA on BP. Several studies investigated the effect of ALA on BP. Most of the papers show no significant effect for supplementation and the studies have shown that associations are limited. However, these findings are limited and there is a need for further and more accurate researches to be clarified.